Panacea Biotec in-licenses novel technology from NIH

[Jacob]

Panacea Biotec in-licenses novel technology from NIH for hair growth
Source: IRIS (09 August 2005)

Panacea Biotec (Q, N,C,F)* Ltd has in licensed a peptide based technology for alopecia management from the National Institute of Health, USA. The patent protected technology for actin- binding peptide(s)/poly peptide(s) stimulates hair growth and regenerates lost hair follicles.

The ability of hair follicles to constantly renew is ensured by the presence of the multipotent stem cell. This peptide(s) appears to stimulate multipotent stem cells at the `bulge region`.

The Company will undertake further development of the technology and the company is initiating the preclinical toxicology studies for which the appropriate formulation has already been prepared. After receiving the necessary regulatory approvals for the toxicology data that will be generated, the company will undertake human clinical trials for the product.

Shares of Panacea Biotec on BSE were lastly traded at Rs 229, up by 1.82 per cent.


http://www.myiris.com/newsCentre/newsPo ... D=livenews

[Tricia]

I hope something good comes from it

[Jacob]

It sounds like it's TB4.

From what I remember of the TB4 discussions way back(at Hairsite)..even the NIH metioned TB4 and something else as the end product that would possibly be used in a topical. Getting TB4 and making your own topical..as we've learned..doesn't seem to be working too well. Besides issues such as concentration and stability...it may need other "active ingredients" to make it effective.

So it'll be interesting to see how each of these companies goes about this. I think it's a good sign that yet another company is interested in TB4

[Tricia]

I found another blurb about it and it does sound like Tb4. I was skeptical about the Tb4 that people were making on their own.

A spokesperson from Panacea Biotec is saying 3 to 4 years to launch the product. Even if it works well, I doubt it would be rolled out that soon.

Panacea Biotec to develop hair loss cure

Saturday, 13 August , 2005, 10:18

In order to tap the lucrative hair-loss cure market, Panacea Biotec has entered into an in-licensing agreement with the National Institute of Health (NIH), US, whereby the Indian company will complete the development of NIH's technology and commercialise the product worldwide based on the technology. The patent-protected technology for actin-binding peptide/poly peptide from NIH stimulates hair growth and regenerates lost hair follicles.

Under the in-licensing agreement, Panacea Biotec will undertake further development of the technology. It will initiate the pre-clinical toxicology studies for which the appropriate formulation has already been prepared.

After receiving the necessary regulatory approvals for the toxicology data that will be generated, the company will undertake human clinical trials for the product.

Speaking to Business Line, Rajesh Jain, Joint Managing Director, Panacea Biotec said, "We are working with top global institutions to develop novel technology-based products. In 2001, the market for products curing hair loss was estimated to be at around $50 billion worldwide and was growing at 20 per cent. We expect the growth rates to have gone up even more in recent years."

He hoped that the company would be able to launch the product in three-four years.